TP53 and neoplasm: In a recent study, researchers developed a self-assembling nanoparticle using the natural anticancer agent honokiol (HK) (Phase I trial CTR20170822), achieving 100% drug loading and enhanced tumor targeting via the EPR effect while improving p53-selective antitumor immunity with excellent stability and minimal toxicity (106, 107).